Shots:

• The US FDA has approved the IND application to initiate P-Ib dose escalation & expansion trial to assess two dose levels of PTM-101 among untreated patients with borderline resectable and locally advanced PDAC
• The small P-I trial of PTM-101 in 3 pancreatic cancer patients, that will form the basis of the study, showed >40% reduction in overall tumor volume among 2/3 of them with its lowest dose followed by SoC CT; safety profile was favorable & well-tolerated
• PTM-101, developed through PanTher’s Sagittari drug development platform, is a flexible, absorbable film designed for continuous, high-dose delivery of paclitaxel directly to the peritumoral area, maximizing anti-tumor effectiveness & minimizing side effects

Ref: Businesswire | Image: PanTher Therapeutics

Related News:- Verastem Oncology’s Avutometinib Gains the US FDA’s Orphan Drug Designation to Treat Pancreatic Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com